As Breast Cancer Awareness Month begins, we’re humbled to announce that SCOUT® Radar Localization has surpassed a major milestone:
750,000 patients treated—and counting— with wire-free technology.
Read our latest press release: https://t.co/4foUInOZwF
Merit Medical Embosphere Microspheres Achieve CE Mark for Genicular Artery Embolisation to Treat Knee Osteoarthritis. Read our latest press release: https://t.co/VWjf9OxcA7
@Glen_Schlaphoff Congratulations Glen on the years of forward thinking, planning and lobbying you’ve done to set up this facility. What a state-of-the-art set up.
🚨 New Publication 🚨
Final post of 2024... let's talk about the rapidly evolving evidence around pregnancy after uterine artery embolisation, and the myths around UAE and pregnancy.
https://t.co/zy2jWrP5Vl
"We now have level 1 evidence that shows pregnancy after UAE is not just possible, but outcomes comparable to myomectomy ... and similar rate to background age-matched population ... All IRs have a mandate to end the concept that we only treat peri-menopausal patients. In 2024, the pregnancy myth is busted".
It is important that we, as IRs, stop talking about 20 year old concepts and data if we want the uptake of UAE to continue as we intend (see my recent @cvirendo blog post).
#irad #interventionalradiology #fibroid #adenomyosis #pregnancy @MonashSTM@CVIR_Journal@cirsesociety@IRSA_IRs
Yesterday, the Melbourne based team at Merit Medical ANZ got together for morning tea to raise money for the National Breast Cancer Foundation. Donuts, cupcakes, fruit, pastries, tea and coffee, but most importantly funds were raised!
https://t.co/ASVrha8Fe9
#TeamMerit#WeCare
Merit Medical ANZ would like to send a sincere thank you to @marklittle_IR, Dr Nicholas Brown & @DrChrisRogan for the leading our ANZ Symposium on the treatment of Synovial Arterial Hypervascularity of the Knee Joint. Great presentations, data & discussion.
#WeCare#TeamMerit
Merit Medical’s WRAPSODY WAVE Trial Demonstrates Superior Patency versus Standard of Care in AV Fistula Patients. Read our latest press release: https://t.co/owvayGDf6L
The Merit WRAPSODY Cell-Impermeable Endoprosthesis is not approved or available for commercial distribution in the United States.
Exciting news! This week, @AlfredHealth enrolled the first patient into the BETTER-UAE trial!
"A Prospective, Multi-Center Study using Bearing nsPVA Embolization Particles for the Treatment of uTErine fibRoids with Uterine Artery Embolization: BETTER-UAE".
This prospective cohort study looks at safety and clinical efficacy of @Merit_IR Bearing nsPVA particles to treat fibroids, and will use clinical outcome QoL data to perform a cost effectiveness analysis.
I am very grateful to be the global PI for this trial, and hope that the outcome data will show governments and healthcare systems why it is so important to support and adequately resource low cost pinhole treatments for our patients. Thanks to the clinical and research team (pictured) for the amazing effort!
#fibroids #HMB #research #clinicaltrial #womenshealth #irad #interventionalradiology
@MonashSTM@IRSA_IRs@cirsesociety@BSIR_News@SIRspecialists@GGohIR@AdilFZia@RANZCRcollege@troyjantzen@SalamFindakly@markbolger84
Last week our commercial team partnered with @fareshare_aus to prepare meals for those in need. Collectively as a team we;
- prepared 900 meals
- cut up 30kg of snow peas
- cut up 100kg broccoli
- cut up 120kg mushrooms
- trayed up 200kg tomatoes for cooking.
#TheMeritWay
Thanks @IN_publishing for including an article on my talk at #ET2024 discussing the background and rationale for the EmboCube study.
It is imperative that we have the evidence to support what we do, and follow proper clinical governance pathways protect our patients. Too often, many IRs treat first and ask questions later. This is akin to the specialty of IR shooting oneself in the foot.
https://t.co/lyZZUAiCPR
@cirsesociety@IRSA_IRs@Merit_IR@troyjantzen